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ABSTRACT
Objective: Stroke is one of the leading causes of mortality and long-term disability in both developed and developing countries. Serum homocysteine 
level is one of the emerging modifiable risk factors for atherosclerosis which may result into a cerebrovascular accident. This study was designed to 
study the association of Serum Homocysteine level with the development of acute stroke at a rural tertiary care centre in North India.
Methods: The present study was a prospective cross-sectional study conducted in the Department of Medicine, Maharishi Markandeshwar Institute of 
Medical Sciences and Research, Mullana, Ambala. The study population included 100 patients presenting with Stroke (either ischemic or hemorrhagic) 
in the indoor and outdoor facilities in the Department of Medicine. 50 age and sex-matched healthy individuals were taken as controls. Serum total 
Homocysteine level was measured in all the cases and controls.
Results: Majority of the patients suffered from ischemic stroke (78%), while only 22% patients had hemorrhagic stroke. The mean Serum 
Homocysteine level in stroke patients (19.88±8.78 µmol/l) was significantly higher than in controls (10.48±4.39 µmol/l) (p<0.01). In a subgroup 
analysis, stroke patients with a positive history of smoking had significantly higher homocysteine level as compared to non-smokers (p<0.05).
Conclusion: Increased level of Serum Homocysteine is significantly associated with risk of cerebrovascular accident, which is independent of the risk 
attributed to traditional risk factors.
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INTRODUCTION
Vascular disease of the brain remains a very important cause of 
neurologic morbidity and mortality. Stroke is a cerebrovascular 
disorder resulting in the rapidly developing loss of brain functions. 
This can be due to ischemia or hemorrhage. Stroke is one of 
the leading causes of mortality and long-term disability in both 
developed and developing countries. There are various non-
modifiable and modifiable risk factors for stroke [1]. Plasma 
homocysteine concentration is one of the emerging modifiable risk 
factors for atherosclerosis which may manifest as a cerebrovascular 
accident [2,3].
Homocysteine is a sulfhydryl amino acid that is readily oxidized to 
homocysteine and homocysteine-cysteine mixed disulfide in the 
plasma. Mechanisms by which hyperhomocysteinemia increases 
risk of cerebrovascular accidents are not clear, but several possible 
mechanisms have been proposed [4]. Hyperhomocysteinemia is 
associated with premature atherosclerosis. Experimental studies 
both in vivo and in vitro show that homocysteine causes endothelial 
injury and cell detachment. Endothelial cell injury, platelet activation, 
deleterious effect on thrombomodulin expression, protein C 
activation, and an increased oxidizability of low-density lipoprotein 
have been described as a few possible mechanisms by which 
homocysteine provokes arteriosclerosis and thrombosis [5,6]. Animal 
studies have also shown that raised Homocysteine levels may induce 
marked remodeling of the extracellular matrix in the arterial wall [7]. 
An ideal homocysteine level is <9 μmol/L. Hyperhomocysteinemia 
is the term used for elevated levels of homocysteine in plasma, 
i.e., >15 μmol/L.
India, with more than 1 billion inhabitants, is undergoing remarkable 
economic and demographic changes in recent years. This has resulted 
in a rapid increase in lifestyle related noncommunicable disorders 
including cardiovascular and cerebrovascular diseases. Given the 
anticipated increase in the burden of stroke in coming years and 
limited availability of organized stroke care services to the majority of 
people in India, it is important to place greater emphasis on population-
based stroke prevention strategies. The present study is, therefore, 
undertaken to look for the association between Serum Homocysteine 
and cerebrovascular accidents.
METHODS
The present study was a prospective cross-sectional study conducted in the 
Department of Medicine, Maharishi Markandeshwar Institute of Medical 
Sciences and Research, Mullana, Ambala. The study population included 
100 patients presenting with Stroke (either ischemic or hemorrhagic) in 
the indoor and outdoor facilities in the Department of Medicine. 50 age 
and sex-matched healthy individuals were taken as controls. The study 
was done in 2012–2013 after approval from the Ethical Committee of the 
institute. The total duration of the study was 1 year.
Inclusion criteria
The following criteria were included in this study:
1. Patient diagnosed with stroke
2. Age >18 years.
Stroke was defined as rapidly developing signs of a focal or global 
neurological deficit with no apparent cause other than vascular, 
documented by computed tomography (CT) or magnetic resonance 
imaging done within 24 h of admission.
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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Exclusion criteria
The following criteria were excluded from this study:
1. Previous history of ischemic or valvular heart disease
2. Peripheral vascular disease
3. Epilepsy
4. Renal impairment
5. Drugs that affect homocysteine, Vitamin B12, and Folate metabolism, i.e., 
fibrates, statins and niacin, methotrexate, sulfasalazine, anticonvulsant 
drugs, levodopa, oral contraceptives, anticoagulant therapy, and
6. Pregnancy.
After fulfilling the inclusion and exclusion criteria, all the study subjects 
were explained about the study design in detail, and a written informed 
consent was taken from all cases as well as controls. Detailed clinical 
history (including present and past medical illness) and treatment 
history were noted. Baseline demographic data (age and sex) and 
conventional cardiovascular risk factors, including diabetes mellitus 
(DM), hypertension (HT), hyperlipidemia, smoking, and previous 
coronary diseases, were recorded for the patients and controls. 
Complete clinical examination including a detailed neurological 
assessment was done in all patients. All patients underwent routine 
laboratory investigations (Hemoglobin, random blood sugar, renal 
and liver function tests, and electrocardiogram) and also radiological 
investigations including CT scan as required.
Measurement of serum homocysteine level
Serum total homocysteine level was measured in all the study subjects 
using the standard technique. 2 ml of fasting blood sample were 
collected to obtain serum. Fasting total serum total homocysteine level 
was estimated by auto pure automated analyzer (marketed by Accurex) 
with a normal range of 5–15 μmol/l.
Statistical analysis
The statistical analysis was carried out using SPSS version 13-computer 
software. The data for continuous variables were expressed as 
Mean±SD., and categorical data were expressed as frequencies and 
percentages. p<0.05 was considered significant.
RESULTS AND OBSERVATIONS
A total of 100 cases of Stroke and 50 controls were evaluated in this 
study. The baseline demographic and clinical characteristics of cases 
and controls are shown in Table 1. There was no statistically significant 
difference in the two groups with regard to age and sex. The mean 
age in stroke patients and controls was 59.02 years and 56.44 years, 
respectively (p>0.05). Maximum number of cases of stroke were in the 
age group of 61–70 years (36%) followed by 51–60 years age group 
(23%). Majority of stroke patients were males (68%). Body mass index 
(BMI), systolic blood pressure, and diastolic blood pressure were 
significantly higher in stroke patients as compared to controls (p<0.05). 
Majority of the patients suffered from ischemic stroke (78%), while 
only 22% patients had a hemorrhagic stroke.
Table 2 shows the comparison of serum homocysteine level between 
cases and controls. The mean serum homocysteine level in stroke 
patients (19.88±8.78 µmol/l) was significantly higher than in controls 
(10.48±4.39 µmol/l) (p<0.01).
Table 3 shows the Serum Homocysteine level in stroke patients sub-
grouped according to the presence of established risk factors of stroke. 
Serum Homocysteine level was significantly higher in stroke patients 
with a history of smoking as compared to non-smokers (p<0.05). No 
significant difference was seen in Serum Homocysteine levels with 
relation to other risk factors (HT, DM, BMI, and family history).
The comparison of Serum Homocysteine level in patients with 
ischemic and Hemorrhagic Stroke is shown in Table 4. Mean 
homocysteine levels in ischemic and hemorrhagic stroke were 20.27 
and 19.76 µmol/l, respectively, which was statistically non-significant 
(p>0.05).
DISCUSSION
Stroke is a major health problem worldwide and is one of the leading 
causes of mortality and long-term disability. Ischemic stroke accounts 
for more than 80% patients of stroke worldwide [8]. In the present study, 
78 patients had ischemic stroke while only 22 patients presented with 
Hemorrhagic Stroke. Primary and secondary prevention by managing 
the various modifiable risk factors for stroke is the key to reducing 
the incidence of stroke and its impact on health-care resources [9]. 
Hyperhomocysteinemia is one of the recently recognized modifiable 
factors that increase the risk of cardiovascular and cerebrovascular 
disease [4].
Table 1: Comparison of baseline characteristics between cases and control groups
Parameter Cases 100 (%) Control 50 (%) p value
Age (in years) (Mean±SD) 59.02±10.26 56.44±13.43 0.193
Gender (n, %)
Males 68 (68) 32 (64) 0.624
Females 32 (32) 18 (36)
BMI (in kg/m2) (Mean±SD) 22.19±2.51 20.04±1.83 <0.05*
Stroke risk factors (n, %)
Smoking 26 (26) 12 (24) 0.791
DM 29 (29) 6 (12) 0.022*
HT 48 (48) 8 (16) <0.01**
Dyslipidemia 11 (11) 6 (12) 0.855
Obesity 18 (18) 5 (10) 0.067
Positive family history 8 (8) 2 (4) 0.422
SBP (mm Hg) (Mean±SD) 150.41±21.83 128.52±17.06 <0.01**
DBP (mm Hg) (Mean±SD) 89.22±11.60 79.6±9.45 <0.01**
Type of stroke (n, %)
Ischemic 78 (78)
Hemorrhagic 22 (22)
(*p<0.05-significant, P<0.01 highly significant). BMI: Body mass index, DM: Diabetes mellitus, HT: Hypertension, SBP: Systolic blood pressure, DPB: Diastolic blood 
pressure
Table 2: Comparison of serum homocysteine level between 
cases and controls
Gender Serum homocysteine 
level in µmol/l (Mean±SD)
p value
Cases Controls
Overall 19.88±8.78 10.48±4.39 <0.01**
Males 19.94±8.91 10.56±4.41 <0.01**
Females 19.75±8.65 10.33±4.54 <0.01**
(*p<0.05-significant, P<0.01 highly significant)
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In the present study, we evaluated the association of Serum 
total Homocysteine level with Stroke. Hyperhomocysteinemia is 
defined as serum homocysteine level >15 µmol/l. In our study, the 
proportion of stroke patients with hyperhomocysteinemia (44%) 
was significantly higher than that seen in controls (8%). The mean 
fasting Serum Homocysteine level in stroke patients (19.88±8.78 
µmol/l) was significantly higher than the controls (10.48±4.39 
µmol/l) (p<0.01). Furthermore, on subgroup analysis based on gender, 
significantly higher homocysteine levels were seen in male stroke 
patients as compared to control males (19.94±8.91 vs. 10.56±4.41, 
p<0.01) as well as in female stroke patients as compared to control 
females (19.75±8.65 vs. 10.33±4.54, p<0.01). Our findings are in 
agreement with results of previous studies done to evaluate the role 
of Homocysteine as a risk factor for stroke in different demographic 
populations [10-14]. In a nested case–control study done prospectively 
within the British Regional Heart Study cohort, Perry et al. evaluated 
the relation between serum total homocysteine level (tHcy) and risk 
of stroke in the middle‑aged British men. Serum homocysteine was 
measured in 107 cases and 118 control men. tHcy concentrations were 
significantly higher in cases than controls (geometric mean 13.7 vs. 
11.9; p=0.004). This association was found to be present even after 
adjustment for factors such as age group, town, social class, body mass 
index, hypertensive status, cigarette smoking, and diabetes. Their 
findings showed that Homocysteine is an independent predictor of 
cerebrovascular disease [10].
In a similar prospective case–control study in Japanese subjects 40–
85 years of age, serum Homocysteine levels were compared between 
150 patients of incident strokes and controls. Compared with control 
subjects, total (n=150), hemorrhagic (n=52), and ischemic (n=98) 
strokes had higher geometric mean values of total homocysteine. 
They concluded that high total Homocysteine levels were associated 
with the increased risk of stroke, more specifically ischemic stroke 
and lacunar infarction, among Japanese men and women [11]. In 
an Indian study, Narang et al. evaluated the role of homocysteine 
as a risk factor for ischemic stroke. Serum Homocysteine level was 
measured in 117 patients of ischemic stroke and 101 controls. The 
mean homocysteine levels in patients with ischemic stroke were 16.80 
micromol/l while in controls it was 12.30 micromol/l which was 
statistically significant (p<0.01). The increased homocysteine levels in 
patients with ischemic stroke were found to be independent of factors 
such as presence of DM, age, and sex [12].
In a subgroup analysis of our data, we compared the Serum 
Homocysteine level between subgroups of stroke patients based on 
the presence or absence of Stroke risk factors. Our results showed that 
stroke patients with a positive history of smoking had significantly 
higher homocysteine level as compared to non-smokers (p<0.05). 
There was no significant difference in homocysteine level in stroke 
patients divided on the basis of other risk factors such as age, HT, DM, 
BMI, and Family History. Similar results were seen in a study done on 
Iranian stroke patients where homocysteine levels were shown to be 
significantly higher in smokers than the non-smokers [14].
In our study, 78 patients had ischemic stroke whereas 22 patients had a 
hemorrhagic stroke. The mean homocysteine level in both the subtypes 
was significantly higher than that in controls (p<0.05). On comparing 
the two subtypes of stroke, it was found that mean serum homocysteine 
level in ischemic stroke patients (20.47±9.74) was higher than that of 
hemorrhagic stroke patients (17.36±7.44), although this difference was 
not found to be statistically significant (p>0.05). Although the role of 
homocysteine in ischemic stroke has been established by many studies 
in the past, its role in Hemorrhagic Stroke is still uncertain. In a meta-
analysis done to evaluate the association between elevated plasma 
homocysteine levels and the risk of different types of strokes, He et al. 
showed that although elevated Homocysteine levels are associated with 
an increased risk for ischemic strokes and recurrent strokes they showed 
no distinct association with hemorrhagic strokes [15]. On the contrary, 
in a recent systematic review and meta-analysis, Zhou et al. showed 
that Hcy level in patients of intracerebral bleed was significantly higher 
than that in healthy  controls. They suggested that high homocysteine 
level may act by aggravating the process of atherosclerosis, which is 
positively associated with a high risk of intracranial hemorrhage [16].
CONCLUSION
Increased level of serum Homocysteine is significantly associated 
with risk of cerebrovascular accident, which is independent of the risk 
attributed to traditional risk factors.
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